Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 12/2016

10.08.2016 | Editorial Commentary

How reliable is 18FDG PET for predicting the onset of Huntington’s disease?

verfasst von: Andrea Ciarmiello

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Excerpt

In the current issue of the European Journal of Nuclear Medicine and Molecular Imaging, López-Mora et al. present a study evaluating the cortical and striatal 18F-FDG PET/CT uptake in a cohort of Huntington’s disease (HD) mutation carriers in preclinical and manifest stages of the disease. The authors found a progressive metabolic striatal decrease in subjects with preclinical HD as compared with controls and subjects with manifest HD, indicating the value of 18F-FDG PET/CT as a possible predictor of the onset of HD. The findings are consistent with those of previous studies highlighting early striatal involvement in gene mutation carriers without motor symptoms and, therefore, still clinically considered far from onset. …
Literatur
1.
The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–83.CrossRef
2.
Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330(20):1401–6.CrossRefPubMed
3.
Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–48.CrossRefPubMed
4.
Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR; International Huntington’s Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4):267–77.CrossRefPubMed
5.
Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci U S A. 2004;101(10):3498–503.CrossRefPubMedPubMedCentral
6.
Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet. 1993;4(4):398–403.CrossRefPubMed
7.
Telenius H, Kremer HP, Theilmann J, Andrew SE, Almqvist E, Anvret M, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet. 1993;2(10):1535–40.CrossRefPubMed
8.
Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franz ML, et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet. 1995;57(3):593–602.PubMedPubMedCentral
9.
Kuhl DE. Imaging local brain function with emission computed tomography. Radiology. 1984;150(3):625–31.CrossRefPubMed
10.
Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;20(3):296–303.CrossRefPubMed
11.
Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med. 1987;316(7):357–62.CrossRefPubMed
12.
Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23(6):541–6.CrossRefPubMed
13.
Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology. 1986;36(7):888–94.CrossRefPubMed
14.
Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47(2):215–22.PubMed
15.
Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA. Correlation between the onset age of Huntington’s disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet. 1993;2(10):1547–9.CrossRefPubMed
16.
Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39(6):1030–6.CrossRefPubMed
17.
van Duijn E, Kingma EM, Timman R, Zitman FG, Tibben A, Roos RA, et al. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington’s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry. 2008;69(11):1804–10.CrossRefPubMed
18.
Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain. 2007;130(Pt 11):2858–67.CrossRefPubMedPubMedCentral
19.
Ginsberg MD, Lockwood AH, Busto R, Finn RD, Butler CM, Cendan IE, et al. A simplified in vivo autoradiographic strategy for the determination of regional cerebral blood flow by positron emission tomography: theoretical considerations and validation studies in the rat. J Cereb Blood Flow Metab. 1982;2(1):89–98.CrossRefPubMed
20.
Howard BE, Ginsberg MD, Hassel WR, Lockwood AH, Freed P. On the uniqueness of cerebral blood flow measured by the in vivo autoradiographic strategy and positron emission tomography. J Cereb Blood Flow Metab. 1983;3(4):432–41.CrossRefPubMed
21.
Ciarmiello A, Giovannini E, Meniconi M, Cuccurullo V, Gaeta MC. Hybrid SPECT/CT imaging in neurology. Curr Radiopharm. 2014;7(1):5–11.CrossRefPubMed
Metadaten
Titel
How reliable is 18FDG PET for predicting the onset of Huntington’s disease?
verfasst von
Andrea Ciarmiello
Publikationsdatum
10.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3483-5

Weitere Artikel der Ausgabe 12/2016

European Journal of Nuclear Medicine and Molecular Imaging 12/2016 Zur Ausgabe

Editorial Commentary

PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer

Original Article

Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer

Editorial Commentary

ImmunoPET to help stratify patients for targeted therapies and to improve drug development

Image of the Month

99mTc-DPD-scintigraphy with intense uptake in fat tissue caused by AL-amyloidosis

Original Article

TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib

Guidelines

Guidelines to PET measurements of the target occupancy in the brain for drug development